J Ross1, A Jiamsakul2, N Kumarasamy3, I Azwa4, T P Merati5, C D Do6, M P Lee7, P S Ly8, E Yunihastuti9, K V Nguyen10, R Ditangco11, O T Ng12, J Y Choi13, S Oka14, A H Sohn1, M Law2. 1. TREAT Asia/amfAR -The Foundation for AIDS Research, Bangkok, Thailand. 2. The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia. 3. Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India. 4. Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 5. Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia. 6. Bach Mai Hospital, Hanoi, Vietnam. 7. Queen Elizabeth Hospital, Hong Kong SAR, Hong Kong. 8. National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. 9. Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. 10. National Hospital for Tropical Diseases, Hanoi, Vietnam. 11. Research Institute for Tropical Medicine, Muntinlupa City, Philippines. 12. Tan Tock Seng Hospital, Singapore, Singapore. 13. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 14. National Center for Global Health and Medicine, Tokyo, Japan.
Abstract
OBJECTIVES: To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. METHODS: Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and genotypic resistance testing were collected or testing was conducted between July 2015 and May 2017 at 12 Asia-Pacific sites. Virological failure (VF) was defined as VL > 1000 copies/mL with a second VL > 1000 copies/mL within 3-6 months. FASTA files were submitted to Stanford University HIV Drug Resistance Database and RAMs were compared against the IAS-USA 2019 mutations list. VF risk factors were analysed using logistic regression. RESULTS: Of 1378 patients, 74% were male and 70% acquired HIV through heterosexual exposure. At second-line switch, median [interquartile range (IQR)] age was 37 (32-42) years and median (IQR) CD4 count was 103 (43.5-229.5) cells/µL; 93% received regimens with boosted protease inhibitors (PIs). Median duration on second line was 3 years. Among 101 patients (7%) with VF, CD4 count > 200 cells/µL at switch [odds ratio (OR) = 0.36, 95% confidence interval (CI): 0.17-0.77 vs. CD4 ≤ 50) and HIV exposure through male-male sex (OR = 0.32, 95% CI: 0.17-0.64 vs. heterosexual) or injecting drug use (OR = 0.24, 95% CI: 0.12-0.49) were associated with reduced VF. Of 41 (41%) patients with resistance data, 80% had at least one RAM to nonnucleoside reverse transcriptase inhibitors (NNRTIs), 63% to NRTIs, and 35% to PIs. Of those with PI RAMs, 71% had two or more. CONCLUSIONS: There were low proportions with VF and significant RAMs in our cohort, reflecting the durability of current second-line regimens.
OBJECTIVES: To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. METHODS: Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and genotypic resistance testing were collected or testing was conducted between July 2015 and May 2017 at 12 Asia-Pacific sites. Virological failure (VF) was defined as VL > 1000 copies/mL with a second VL > 1000 copies/mL within 3-6 months. FASTA files were submitted to Stanford University HIV Drug Resistance Database and RAMs were compared against the IAS-USA 2019 mutations list. VF risk factors were analysed using logistic regression. RESULTS: Of 1378 patients, 74% were male and 70% acquired HIV through heterosexual exposure. At second-line switch, median [interquartile range (IQR)] age was 37 (32-42) years and median (IQR) CD4 count was 103 (43.5-229.5) cells/µL; 93% received regimens with boosted protease inhibitors (PIs). Median duration on second line was 3 years. Among 101 patients (7%) with VF, CD4 count > 200 cells/µL at switch [odds ratio (OR) = 0.36, 95% confidence interval (CI): 0.17-0.77 vs. CD4 ≤ 50) and HIV exposure through male-male sex (OR = 0.32, 95% CI: 0.17-0.64 vs. heterosexual) or injecting drug use (OR = 0.24, 95% CI: 0.12-0.49) were associated with reduced VF. Of 41 (41%) patients with resistance data, 80% had at least one RAM to nonnucleoside reverse transcriptase inhibitors (NNRTIs), 63% to NRTIs, and 35% to PIs. Of those with PI RAMs, 71% had two or more. CONCLUSIONS: There were low proportions with VF and significant RAMs in our cohort, reflecting the durability of current second-line regimens.
Authors: David C Boettiger; Van K Nguyen; Nicolas Durier; Huy V Bui; Benedict L Heng Sim; Iskandar Azwa; Matthew Law; Kiat Ruxrungtham Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Beatriz Grinsztejn; Michael D Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T Schooley; John W Mellors; Carole L Wallis; Ann C Collier Journal: Lancet HIV Date: 2019-07-29 Impact factor: 12.767
Authors: Julie H Levison; Catherine Orrell; Sébastien Gallien; Daniel R Kuritzkes; Naishin Fu; Elena Losina; Kenneth A Freedberg; Robin Wood Journal: PLoS One Date: 2012-03-13 Impact factor: 3.240
Authors: Cleophas Chimbetete; David Katzenstein; Tinei Shamu; Adrian Spoerri; Janne Estill; Matthias Egger; Olivia Keiser Journal: Open Forum Infect Dis Date: 2018-02-02 Impact factor: 3.835
Authors: Holly E Rawizza; Beth Chaplin; Seema T Meloni; Kristin M Darin; Oluremi Olaitan; Kimberly K Scarsi; Chika K Onwuamah; Rosemary A Audu; Philippe R Chebu; Godwin E Imade; Prosper Okonkwo; Phyllis J Kanki Journal: PLoS One Date: 2013-09-17 Impact factor: 3.240
Authors: Denise Evans; Kamban Hirasen; Rebecca Berhanu; Given Malete; Prudence Ive; David Spencer; Sharlaa Badal-Faesen; Ian M Sanne; Matthew P Fox Journal: AIDS Res Ther Date: 2018-04-10 Impact factor: 2.250